Case Study: Amgen’s Pioneering Integration of AI to Accelerate Innovation and Drug Discovery

At Amgen, artificial intelligence (AI) is more than just a technological advancement—it’s a pivotal force transforming the future of biotechnology. Under the guidance of David Reese, Amgen’s first chief technology officer, AI is being integrated across all operational levels to enhance productivity, foster innovation, and accelerate the development of new therapies.

Key Takeaways

• Amgen is using AI to enhance productivity and innovation in both administrative and laboratory settings.
• AI tools are enabling rapid simulations and modeling, significantly accelerating drug discovery processes.
• Partnerships with technology leaders like Microsoft, NVIDIA, and AWS are crucial to Amgen’s AI initiatives.

Approach

Amgen’s approach to integrating AI involves a broad adoption of AI tools across all facets of the company, aiming to streamline tasks and enhance productivity. Central to this approach are partnerships with leading technology companies such as Microsoft, NVIDIA, and AWS, which provide access to cutting-edge AI technologies. Additionally, Amgen focuses on generative biology, using AI to model protein-based molecules and simulate their interactions with disease targets, which accelerates the discovery of effective therapies.

Implementation

Amgen was an early adopter of Microsoft Copilot, a generative AI productivity tool. Initially tested by a small group of employees, its use has now expanded to 20,000 employees. This tool helps streamline repetitive tasks, freeing up time for higher-level challenges and innovation.

In the laboratory, AI is revolutionizing drug discovery. Amgen uses NVIDIA’s AI models to tackle complex operations like generative biology. This involves using AI to generate models of protein-based molecules and run simulations to predict their effectiveness and safety. Additionally, Amgen’s installation of an NVIDIA DGX SuperPOD supercomputer, Freyja, at their subsidiary deCODE genetics, enables the analysis of vast amounts of human data to uncover new health insights.

Amgen is expanding its work with AWS to create generative AI-based solutions to enhance manufacturing throughput and operational efficiency. This includes implementing a connected digital platform using Amazon SageMaker for real-time data analysis and predictive maintenance.

Results

The integration of AI at Amgen has led to significant achievements. Productivity has increased as AI tools reduce the time required for data aggregation and analysis, allowing scientists to focus more on innovation. The drug discovery process has been accelerated, with AI-driven models enabling the rapid identification and development of promising drug candidates, some of which were previously considered unsolvable. In manufacturing, AI solutions from AWS have improved processes, reducing downtime and increasing efficiency, ultimately helping Amgen deliver medicines faster to patients.

Challenges and Barriers

Despite the significant potential of AI, Amgen faces several challenges. Managing and analyzing vast amounts of data requires robust infrastructure and advanced tools. Successful AI implementation also necessitates collaboration between computer scientists and wet lab scientists to ensure practical and relevant applications. Additionally, equipping employees with the necessary skills to use AI tools effectively is an ongoing challenge that Amgen must address to maximize the benefits of its AI initiatives.

Future Outlook

Amgen’s continued investment in AI promises to drive further innovation in biotechnology. The future likely holds the development of more sophisticated AI models for drug discovery and development, as well as increased automation in laboratories, with AI models interacting directly with robotic systems. Furthermore, Amgen is focusing on attracting and developing talent from diverse backgrounds to bridge the gap between AI and biology, ensuring a rich pool of ideas and approaches to drive innovation.

To get the latest AI transformation case studies straight to your inbox, subscribe to AI in Action by AIX — your weekly newsletter dedicated to the exploration of AI adoption in business.

Elevate your understanding of AI transformation. Browse AI adoption case studies searchable by company, industry, use case, and technology.

Sources:
From the Office to the Lab, Amgen Uses AI Tools to Unlock Innovation
Tackling the “Impossible” in Biotechnology with AI
Amgen to Build Generative AI Models for Novel Human Data Insights and Drug Discovery
AWS Joins Forces With Amgen on Generative AI Solutions to Accelerate Advanced Therapies

Let’s talk

Whether you’re looking for expert guidance on AI transformation or want to share your AI knowledge with others, our network is the place for you. Let’s work together to build a brighter future powered by AI.